Accustem Sciences (ACUT) Share-based Compensation (2021 - 2026)
Accustem Sciences (ACUT) posted quarterly Share-based Compensation of $15161.0 for Q1 2026, down 16.27% year-over-year from $18107.0 in Q1 2025, and down 96.95% quarter-over-quarter from $497867.0 in Q2 2025.
Accustem Sciences (ACUT) Share-based Compensation (2021 - 2026) Analysis & Trends
Accustem Sciences (ACUT) has reported Share-based Compensation for 6 consecutive years, with $15161.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 16.27% year-over-year to $15161.0; the TTM figure through Mar 2026 stood at $33268.0 (down 9.79% YoY), while the FY2025 annual figure was $1.5 million, up 107.29% from the prior year.
- Share-based Compensation declined to $15161.0 in Q1 2026 per ACUT's latest filing, from $497867.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $846453.0 in Q1 2023 and bottomed at $12626.0 in Q2 2023.
- Historically, Share-based Compensation has averaged $197311.4 across 5 years, with a median of $19899.5 in 2023.
- Annual changes were most pronounced in 2023 — Share-based Compensation surged 4867.45% — and 2025, when it plunged 97.8%.
- Accustem Sciences' Share-based Compensation stood at $41260.0 in 2022, then plunged by 51.77% to $19899.0 in 2023, then declined by 5.67% to $18771.0 in 2024, then surged by 2552.32% to $497867.0 in 2025, then slumped by 96.95% to $15161.0 in 2026.
- Business Quant data shows ACUT's Share-based Compensation at $15161.0 in Q1 2026, $497867.0 in Q2 2025, and $18107.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | - |
| 10 | Accustem Sciences | 2.57 Mn | 2.56 Mn | - | 428,057.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15,161.00 |
| Mar 31, 2026 | 15,161.00 |
| Jun 30, 2025 | 497,867.00 |
| Jun 30, 2025 | 497,867.00 |
| Mar 31, 2025 | 18,107.00 |
| Mar 31, 2025 | 18,107.00 |
| Dec 31, 2024 | 18,771.00 |
| Dec 31, 2024 | 18,771.00 |
| Mar 31, 2024 | 822,652.00 |
| Mar 31, 2024 | 822,652.00 |
| Dec 31, 2023 | 19,899.00 |
| Dec 31, 2023 | 19,899.00 |
| Sep 30, 2023 | 19,900.00 |
| Sep 30, 2023 | 19,900.00 |
| Jun 30, 2023 | 12,626.00 |
| Jun 30, 2023 | 12,626.00 |
| Mar 31, 2023 | 846,453.00 |
| Mar 31, 2023 | 846,453.00 |
| Dec 31, 2022 | 41,260.00 |
| Dec 31, 2022 | 41,260.00 |